NURO News and Press, NeuroMetrix Inc. From 10/20/22

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on in...

WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on Oct 20, 2...

Summary DPNCheck is a screening product sold to MA insurers which gives better member health outcomes, lower cost, and increased revenue for MA insurers. The product has consistently grown >20%. Discontinuation of Quell marketing in 2018 is masking the strong, underlying growth...

WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription w...

NeuroMetrix ( NASDAQ: NURO ) stock fell ~4% on July 21 after the company reported a decline in Q2 revenue and a widened net loss. YTD, the stock has shed over -28% . See chart here . Revenues fell -3.4% Y/Y to to $2.13M Y/Y. The company said its Quell ove...

NeuroMetrix, Inc. (NURO) Q2 2022 Earnings Conference Call July 21, 2022 08:00 ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - President and Chief Executive Officer Presentation Operator Good...

NeuroMetrix press release ( NASDAQ: NURO ): Q2 GAAP EPS of -$0.17. Revenue of $2.1M (-5.0% Y/Y). For further details see: NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individ...

WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21...

WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experi...